OraSure Technologies (NASDAQ:OSUR) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

OraSure Technologies (NASDAQ:OSUR) announced its earnings results on Wednesday. The medical instruments supplier reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08), FiscalAI reports. OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Management expects mid-year FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and the Colli?Pee at?home urine collection device, with revenue ramps anticipated in the second half of 2026.
• Q1 revenue was $27.9 million (above guidance midpoint) and non?GAAP gross margin expanded to 43.4%, driven by insourcing production into its Pennsylvania facilities and improved operating efficiencies.
• OraSure finished Q1 with $177 million cash and zero debt while returning $20 million to shareholders via buybacks over the last four quarters, but operating cash flow was negative $14 million with management targeting break?even cash flow in 2027.
• International progress includes initial orders to a nearshoring partner, planned follow?on orders in H2, and expanded reach for Sickle SCAN via BioMedomics integration and national health program relationships.
• Operating expenses remain elevated—Q1 R&D was $13.7 million (launch preparation) and G&A rose due to severance and one?time items—contributing to a GAAP operating loss of $23.3 million, though management expects R&D and G&A to normalize later in 2026.

OraSure Technologies Price Performance

NASDAQ OSUR remained flat at $3.00 during trading hours on Wednesday. 583,251 shares of the company’s stock were exchanged, compared to its average volume of 324,072. OraSure Technologies has a 12-month low of $2.08 and a 12-month high of $3.82. The stock has a market capitalization of $215.91 million, a PE ratio of -3.23 and a beta of 0.89. The stock has a 50 day simple moving average of $3.05 and a 200 day simple moving average of $2.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $3.00.

Insiders Place Their Bets

In related news, CEO Manner Carrie Eglinton acquired 32,300 shares of OraSure Technologies stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of $2.93 per share, for a total transaction of $94,639.00. Following the purchase, the chief executive officer directly owned 2,190,874 shares of the company’s stock, valued at $6,419,260.82. The trade was a 1.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kenneth J. Mcgrath acquired 32,300 shares of OraSure Technologies stock in a transaction on Friday, March 20th. The shares were bought at an average price of $2.93 per share, for a total transaction of $94,639.00. Following the completion of the purchase, the chief financial officer directly owned 589,562 shares in the company, valued at $1,727,416.66. The trade was a 5.80% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 108,643 shares of company stock worth $321,407 over the last quarter. 3.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OSUR. Kotler Kevin acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $4,359,000. Millennium Management LLC raised its holdings in shares of OraSure Technologies by 71.1% during the third quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after purchasing an additional 878,151 shares during the period. Archon Capital Management LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter worth $1,388,000. Cannell Capital LLC raised its holdings in shares of OraSure Technologies by 33.7% during the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after purchasing an additional 470,536 shares during the period. Finally, UBS Group AG raised its holdings in shares of OraSure Technologies by 98.2% during the third quarter. UBS Group AG now owns 722,520 shares of the medical instruments supplier’s stock worth $2,319,000 after purchasing an additional 358,016 shares during the period. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.